S*BIO and Onyx Pharmaceuticals Expand Collaboration for JAK2 Inhibitors

S*BIO and Onyx Pharmaceuticals have announced the expansion of their development collaboration and option and license commercialization agreement for the former’s JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively.

Onyx will provide US$20 million in funding to broaden and accelerate the existing development program for both compounds. The program will be expanded to include new indications for hematologic malignancies and myeloproliferative disorders. S*BIO will continue to perform the clinical development of SB1518 (ONX0803) and preclinical through clinical development of SB1578 (ONX0805).

Onyx can elect to exercise its exclusive options for SB1518 (ONX 0803) and SB1578 (ONX 0805) separately and independently at certain predetermined stages of development for each compound in all indications in the US, Canada and Europe.

S*BIO would retain rights to develop and commercialize SB1518 and SB1578 in the rest of the world.